Transaction Overview - OceanFirst Financial Corp 将以全股票方式收购 Flushing Financial Corporation，每股 Flushing 股票兑换 0.8500 股 OceanFirst 股票[42] - Warburg Pincus 将投资 2.25 亿美元用于 OceanFirst 的股权融资，购买价格为每股 19.76 美元[14, 42] - 交易完成后，OceanFirst 股东预计将持有合并后公司约 58% 的股份，Flushing 股东持有约 30%，Warburg Pincus 持有约 12%[42] Financial Impact - 预计 2027 年每股收益 (EPS) 将增加 16%[17, 34] - 有形账面价值 (TBV) 稀释为 (6%)，预计 3.1 年内收回[17, 34] - 预计 2027 年有形普通股报酬率 (ROATCE) 为 12.6%，普通资产报酬率 (ROAA) 为 1.00%[17, 34] Strategic Rationale - 通过 Flushing 在长岛和纽约市的渠道，OceanFirst 能够扩展其产品和服务[14] - 合并后的银行预计总资产将达到 230 亿美元[17, 34] - 合并有助于贷款组合多元化，并降低商业房地产 (CRE) 集中度[14] Risk and Cautionary Notes - 该报告包含前瞻性陈述，涉及风险和不确定性，实际结果可能与预测存在重大差异[4, 5] - 风险包括交易完成的延迟或失败，监管批准的条件，以及整合两家公司业务的潜在困难[5]

Financial Performance - Revenue for Q3 2025 was $14.3 million, compared to $15.2 million in Q3 2024[7] - Like-for-like revenue (excluding discontinued product lines) was $14.2 million in Q3 2025, compared to $14.6 million in Q3 2024[4, 7] - Gross profit increased to $6.5 million in Q3 2025 from $5.3 million in Q3 2024, with gross margin improving to 45.2% from 35.0%[7] - The company achieved positive Adjusted EBITDA of $0.5 million for the quarter, compared to negative $1.4 million in Q3 2024[4] - Net loss was $5.1 million in Q3 2025, compared to $4.8 million in Q3 2024[4] - Basic and diluted loss per ADS was $0.28 in Q3 2025, compared to $0.46 in Q3 2024[4] Key Revenue Drivers - TrinScreen HIV sales were $1.0 million in Q3 2025, compared to $2.4 million in Q3 2024, reflecting the resumption of manufacture[7] - UniGold HIV sales showed strong performance with sales of $2.6 million in Q3 2025, compared to $1.6 million in Q3 2024[7] - Haemoglobin revenue increased to $5.7 million in Q3 2025 from $5.1 million in Q3 2024[7] Expenses and Liquidity - R&D expense was $0.8 million in Q3 2025, compared to $1.0 million in Q3 2024[10] - SG&A expense decreased to $6.2 million in Q3 2025 from $6.5 million in Q3 2024[10] - Cash balance at the end of Q3 2025 was $1.3 million, compared to $2.8 million in Q3 2024[10]

2025Q3 Performance Highlights - Hotel RevPAR was RMB 124, down 84% compared with 2024Q3[14] - Restaurant Average Daily Sales Per Store (ADS) was RMB 3,714, down 241% compared with 2024Q3[14] - Hotel Revenues were RMB 2545 million, down 113% compared with 2024Q3[14] - Hotel Income from Operations was RMB 691 million, down 305% with a margin of 272% compared with 2024Q3[14] - Adjusted Income from Operations was RMB 1093 million, up 36% with a margin of 405% compared with 2024Q3[14] - Net Income was RMB 595 million, up 15% with a margin of 234% compared with 2024Q3[14] - Adjusted Net Income was RMB 905 million, up 57% with a margin of 284% compared with 2024Q3[14] - Adjusted EBITDA was RMB 1150 million, down 61% with a margin of 379% compared with 2024Q3[14] Strategic Execution - Further Expansion into Mid-to-Upscale Segment[43] - Greater Penetration in Tier 3 and Lower Cities in South China[43]

Financial Performance - Revenue for Q2 2025 was $10.8 million, a decrease compared to $15.8 million in Q2 2024[4, 7] - Like-for-like revenue (excluding sub-scale lower-margin third-party product lines) was $10.7 million in Q2 2025, versus $15.0 million in Q2 2024[7] - Gross profit was $4.6 million in Q2 2025, down from $5.7 million in Q2 2024[7] - Gross margin improved to 42.6% in Q2 2025, compared to 36.2% in Q2 2024[7] - Net loss was $6.0 million in Q2 2025, an improvement from $6.8 million in Q2 2024[4] - Basic and diluted loss per ADS was $0.32 in Q2 2025, compared to $0.71 in Q2 2024[4] - Adjusted EBITDA was negative $2.1 million in Q2 2025, compared to negative $1.4 million in Q2 2024[4] Expenses and Liquidity - R&D expense was $0.6 million in Q2 2025, compared to $0.9 million in Q2 2024, with $1.7 million capitalized[10] - SG&A expense was $7.0 million in Q2 2025, up from $6.4 million in Q2 2024, driven by foreign exchange loss and corporate finance activities[10] - Restructuring costs were $0.7 million in Q2 2025, compared to $1.9 million in Q2 2024[10] - Cash balance at the end of Q2 2025 was $1.5 million, down from $5.3 million in Q2 2024[10]

Acquisition Overview - CACI International Inc acquired ARKA Group on December 22, 2025[1] - The acquisition aligns with CACI's disciplined M&A strategy[9] - The transaction is expected to close in Q3 of FY26, subject to regulatory approvals and customary closing conditions[28] Strategic Rationale - ARKA is a leading technology provider to the national security space community[8] - ARKA's technologies are complementary to CACI's in the space domain[8] - The acquisition expands CACI's customer presence within the Intelligence Community (IC) and Department of War (DoW)[8] - The combined entity will be a leading provider of actionable intelligence across all domains[22] Financial Highlights - ARKA has a double-digit revenue growth profile and "low 20%" EBITDA margins[8] - Approximately 90% of ARKA's revenue comes from national security customers[24] - ARKA has a backlog of approximately $600 million[24] - The purchase price is 12.3x ARKA's estimated FY25 EBITDA[28]

Financial Performance Highlights - Achieved a record full year Adjusted Net Income of $3.1 billion[11], significantly outperforming initial guidance due to strong demand and effective cost management[1]. - Adjusted Earnings Per Share (Diluted) reached $2.25, exceeding the December guidance by approximately $0.55[13]. - Adjusted EBITDA for the full year reached $7.2 billion, surpassing the December guidance by approximately $600 million[13]. - Adjusted ROIC exceeded 13%, the highest in nearly 20 years[11]. - Reduced total debt by over $10 billion since early 2023[45]. Q4 2025 Performance - Q4 2025 Adjusted Net Income was $0.45 billion, nearly 2.5 times the levels of Q4 2024[12]. - Q4 2025 Adjusted EBITDA reached $1.48 billion, exceeding guidance of $1.34 billion[12]. - Net yields outperformed guidance by 110 basis points, reaching 5.4% compared to the guided 4.3%[12]. 2026 Outlook - The company projects Net Debt to Adjusted EBITDA ratio of under 3.0x for 2026, inclusive of over $0.8 billion of dividend payments[49]. - Expects Adjusted Net Income of approximately $3.45 billion and Adjusted Earnings Per Share (Diluted) of $2.48 for FY 2026[14]. - Anticipates Adjusted EBITDA of approximately $7.63 billion for FY 2026[14]. Strategic Initiatives - Reinstated dividend payments at an initial rate of $0.15 per share[1]. - Successfully completed a refinancing plan, refinancing $19 billion of debt in 2025[45]. - Simplified capital structure and optimized future debt maturities[46].

Financial Performance - Net revenues increased by 12.3% to $702.7 million in F26 Q1 compared to $625.6 million in F25 Q1[34, 35] - Gross margin increased by 40 bps to 12.7% in F26 Q1 from 12.3% in F25 Q1[34, 35] - Operating income increased to $13.8 million in F26 Q1, compared to an operating loss of $(0.9) million in F25 Q1[34, 35] - Adjusted diluted earnings per share increased to $0.38 in F26 Q1, compared to $(0.03) in F25 Q1[34, 35] Segment Results - Towable RV segment net revenues increased by 15.5% to $293.4 million in F26 Q1 compared to $254.0 million in F25 Q1[37, 38] - Motorhome RV segment net revenues increased by 13.5% to $308.5 million in F26 Q1 compared to $271.7 million in F25 Q1[44, 45] - Marine segment net revenues increased by 2.2% to $92.5 million in F26 Q1 compared to $90.5 million in F25 Q1[51, 52] Market Trends and Outlook - The company expects CY2025 wholesale RV shipments to be between 335,000 and 345,000 units[18] - The company expects CY2026 wholesale RV shipments to be between 315,000 and 345,000 units[18] - Barletta's market share in the U S aluminum pontoon segment reached 9.1% in F26, with an October monthly share of 12.8%[20] Fiscal 2026 Guidance - The company estimates net revenues between $2.8 billion and $3.0 billion for FY26, representing a potential 4% increase at the midpoint compared to $2.80 billion in FY25[65] - The company estimates adjusted earnings per share between $2.10 and $2.80 for FY26, representing a potential 47% increase at the midpoint compared to $1.67 in FY25[65]

Transaction Overview - Volaris and Viva shareholders will combine their holding companies into Volaris' holding company through a merger of equals[15] - Equity holders in Viva will receive newly issued shares of Volaris, and each side will own 50% of the combined holding company on a fully diluted basis[15] - The transaction is expected to close in 2026, subject to shareholders' vote and applicable regulatory approvals[15] Combined Company Strength - The combined company will have a broad network with 86 destinations, 324 routes, and 991 daily flights[20] - As of 3Q'25, Volaris had 225 routes (128 domestic and 97 international) and Viva had 184 routes (140 domestic and 44 international)[16] - As of 3Q'25, Volaris transported 306 million passengers (226 million domestic and 80 million international) and Viva transported 296 million passengers (263 million domestic and 33 million international)[16] - As of 3Q'25, Volaris' revenue was $2991 million and Viva's revenue was $2365 million[16] - As of 3Q'25, Volaris' EBITDAR was $990 million with a 33% margin, and Viva's EBITDAR was $873 million with a 37% margin[16] - As of 3Q'25, Volaris' net debt was $3071 million and Viva's net debt was $1883 million[16] Market Opportunity - There are 39 million Mexican-origin individuals living in the US[22] - There are 101 million national tourists in the Mexican leisure market in 2024[22] - Mexico received $41 billion in foreign direct investment in 2025[22] - Mexico had 120 million air passengers in 2024[22]

Financial Performance & Outlook - Lamb Weston's Q2 2026 net sales increased by 1% compared to Q2 2025, which includes a favorable foreign currency impact of $24 million[28, 30] - North America net sales were flat, with volume up by 8% but price/mix down by 8%[30, 31] - International net sales increased by 4%, but decreased by 1% on a constant currency basis, with volume up by 7% and price/mix down by 8%[31] - Adjusted EBITDA decreased by $9 million, while adjusted gross profit decreased by $16 million[32] - The company reaffirms its fiscal year 2026 outlook, projecting net sales between $635 billion and $655 billion, and adjusted EBITDA between $1 billion and $12 billion[47] Cash Flow & Capital Allocation - The company has approximately $83 million in cash and cash equivalents, and $135 billion available under its revolving credit facility[39] - Net cash provided by operating activities for the first half of fiscal year 2026 was approximately $530 million, with capital expenditures of $156 million[39] - Free cash flow was $375 million, and the company returned $92 million to shareholders through dividends ($52 million) and share repurchases ($40 million)[39] - The board authorized a 3% increase in the quarterly dividend[9, 46] Strategic Initiatives - The company is executing its "Focus to Win" strategy, which includes a cost savings program expected to yield $100 million in savings in fiscal year 2026 and $250 million by the end of fiscal year 2028[9, 19] - Lamb Weston is optimizing its global supply chain, including restarting curtailed production in North America to meet higher demand[9, 15]

Business Verticals & Strategic Initiatives - ProPhase Labs is pursuing near-term cash recovery of over $50 million from COVID-19 receivables through Crown Medical Collections [7, 11, 24, 26, 92] - BE-Smart, an esophageal cancer diagnostic test, targets a $7-14 billion market [8, 34] - Nebula Genomics possesses a 16-petabyte DNA dataset, equivalent to roughly 150 million ancestry SNP-based tests, spanning 130 countries [9, 62] - ProPhase Labs signed a Letter of Intent for a proposed reverse merger with Advanced Biological Laboratories S A (ABL), with ABL potentially becoming the majority owner (~76%) [20, 23] BE-Smart Esophageal Cancer Diagnostic - BE-Smart achieved greater than a 95% technical success rate in a key validation study evaluating its performance with esophageal brush cytology samples [44, 93] - The change in the annual incidence of Esophageal Adenocarcinoma (EAC) was 766 67% higher in 2017 compared to 1973 [32] Nebula Genomics - Nebula Genomics' DNA Complete offers Whole Genome Sequencing (WGS) analyzing virtually 100% of an individual's DNA [63] - DNA Expand expands raw DNA data more than 50 times to over 35 million genetic variants [73] Financial Restructuring - ProPhase Labs sold Pharmaloz Manufacturing for $23 6 million [18] - The company is saving over $6 million per year by shutting down the genomics laboratory [18]